Skip to main
ELAN

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health is poised for positive growth as its flagship product, Simparica Trio, maintains a dominant market share of over 50%, while the anticipated market share for Credelio Quattro is projected to rise to 16.8% by 2026, demonstrating robust market positioning. Furthermore, the company's Advantage Family and Seresto products have exhibited impressive year-over-year growth rates of 33% and 28%, respectively, in the third quarter of 2025, reflecting ongoing strong demand trends. These factors contribute to a favorable outlook on Elanco's financial prospects, underscoring its competitive advantage in the growing animal health sector.

Bears say

Elanco Animal Health's financial outlook is negatively impacted by potential refinancing risks, as indicated by concerns stemming from Dentsply Sirona's recent bond offering priced at 8.375%, which may affect Elanco’s earnings growth in 2026. Despite a revenue increase of approximately 50%, the company's EBITDA margin has declined by a couple of hundred basis points, reflecting challenges in maintaining profitability. Additionally, while the 2Q EBITDA performance showed an outperformance of $28 million, the overall trend points to pressures on margins that could hinder future earnings stability.

ELAN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 8 analysts, ELAN has a Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.